Cognition Therapeutics, Inc. is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD? 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). Two posters summarize proteomic analyses from the Phase 2 SEQUEL study which measured the impact of CT1812 on synapse function as determined by changes in brain wave patterns recorded by quantitative electroencephalogram (EEG).

These posters identify candidate protein biomarkers that correlate with improvements observed in SEQUEL participants treated with CT1812, Cognition?s lead candidate. Among the proteins identified, those that were strongly correlated with CT1812 treatment effects were associated with protein trafficking, autophagy, neuroinflammation and microglial response. The third poster summarizes proteomic analyses from the Phase 1 SPARC study, which was designed to measure the impact of CT1812 on synaptic density.

Pathways identified in these proteomic analyses support a role for CT1812 in modulating Aß biology and neuroinflammation, among other disease-relevant processes. CT1812 is an experimental orally delivered small molecule that penetrates the blood-brain barrier and binds selectively to the sigma-2 (s-2) receptor complex. Preclinical and clinical data demonstrate that this binding results in the displacement of toxic Aß oligomers.

The s-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with Aß oligomers, oxidative stress and other stressors. This damage to sensitive synapses can progress to a loss of synaptic function, which manifests as cognitive impairment and Alzheimer?s disease progression.